Tenax Therapeutics (NASDAQ:TENX) Trading 7.6% Higher

Share on StockTwits

Tenax Therapeutics Inc (NASDAQ:TENX)’s share price traded up 7.6% during mid-day trading on Wednesday . The company traded as high as $1.68 and last traded at $1.55, 404,932 shares were traded during mid-day trading. A decline of 40% from the average session volume of 675,102 shares. The stock had previously closed at $1.44.

Separately, ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.

The firm has a market cap of $8.73 million, a PE ratio of -0.17 and a beta of 1.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.04 and a current ratio of 11.04. The stock’s 50-day moving average price is $1.35.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that Tenax Therapeutics Inc will post -1.45 earnings per share for the current year.

An institutional investor recently bought a new position in Tenax Therapeutics stock. Geode Capital Management LLC purchased a new stake in shares of Tenax Therapeutics Inc (NASDAQ:TENX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 27,658 shares of the specialty pharmaceutical company’s stock, valued at approximately $33,000. Geode Capital Management LLC owned about 1.89% of Tenax Therapeutics at the end of the most recent reporting period. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile (NASDAQ:TENX)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.

Featured Article: Bar Chart

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

IBI Group  Earns Outperform Rating from Raymond James
IBI Group Earns Outperform Rating from Raymond James
Head-To-Head Comparison: SPAR Group  & DynTek
Head-To-Head Comparison: SPAR Group & DynTek
Insider Selling: Cornerstone OnDemand, Inc.  CEO Sells $1,149,120.00 in Stock
Insider Selling: Cornerstone OnDemand, Inc. CEO Sells $1,149,120.00 in Stock
Canaccord Genuity Boosts Exchange Income  Price Target to C$43.00
Canaccord Genuity Boosts Exchange Income Price Target to C$43.00
National Bank Financial Boosts Cascades  Price Target to C$14.50
National Bank Financial Boosts Cascades Price Target to C$14.50
Hauck & Aufhaeuser Analysts Give LEG Immobilien  a €112.00 Price Target
Hauck & Aufhaeuser Analysts Give LEG Immobilien a €112.00 Price Target


 
© 2006-2019 Zolmax.